antiinflammatory drug

(redirected from Loteprednol Etabonate)
Also found in: Acronyms.

antiinflammatory drug 

A drug which inhibits or suppresses most inflammatory responses of an allergic, bacterial, traumatic or anaphylactic origin, as well as being immunosuppressant. They include the corticosteroids (e.g. betamethasone, dexamethasone, fluorometholone, hydrocortisone acetate, loteprednol etabonate, prednisolone, rimexolone, triamcinolone). They are sometimes combined with an antibiotic drug (e.g. betamethasone combined with neomycin or sulfacetamide, dexamethasone combined with neomycin or polymyxin B). Corticosteroids have side effects, such as enhancing the activity of herpes simplex virus, fungal overgrowth, raising intraocular pressure or cataract formation.There are other antiinflammatory drugs that are non-steroidal (NSAID) and have little toxicity. They act mainly by blocking prostaglandin synthesis. These include diclofenac sodium, flurbiprofen sodium, indomethacin, ketorolac, nepafenac and oxyphenbutazone. See immunosuppressants; steroid.
Millodot: Dictionary of Optometry and Visual Science, 7th edition. © 2009 Butterworth-Heinemann
References in periodicals archive ?
In preclinical studies, the AMPPLIFY technology increased delivery of loteprednol etabonate into ocular tissues more than three-fold compared to current LE products by facilitating penetration through the tear film mucins.
Bausch + Lomb said on Monday that its New Drug Application (NDA) for its sub-micron loteprednol etabonate ophthalmic gel, 0.38% has been successfully filed with US Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery.
Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
Received three ANDA approvals: Loteprednol Etabonate Ophthalmic Suspension, 0.5%, Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC), and Azelastine Hydrochloride Nasal Spray, 0.1%
The company has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate, designed for ocular applications, resulting in recently approved Inveltys for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.
It was reported yesterday that the company has raised funds to advance work on KPI-121 eye treatment, a novel nanoparticle formulation of loteprednol etabonate using Kala's MPP technology to enhance penetration into target tissues of the eye.
Prednisolone acetate (Predforte[R]), dexamethasone (Maxidex[R], Dexasine[R]), fluorometholone (Flarex[R], FML[R]) and loteprednol etabonate (Lotemax[R]) are the ophthalmic corticosteroids used in Turkey.
A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
(6) Indeed, the steroid loteprednol etabonate has been shown to be significantly more effective in treating the signs and symptoms of CLGPC compared to a placebo in several randomised controlled trials.
KPI-121 0.25% utilises Kala's Ampplify mucus-penetrating particle Drug Delivery Technology to enhance penetration of loteprednol etabonate into target tissue of the eye.